New antibody targets rare kidney disease

NCT ID NCT07096843

Recruiting now Disease control Sponsor: Climb Bio, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental antibody called budoprutug in adults with primary membranous nephropathy, a rare autoimmune kidney disease. Researchers want to see if the treatment is safe and can help reduce kidney damage by targeting specific immune cells. About 45 participants will receive intravenous doses over several months and be followed for about a year to monitor their response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Climb Bio Investigative Site #101
RECRUITING

Clifton Park, New York, 12065, United States
Climb Bio Investigative Site #102
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Climb Bio Investigative Site #103
RECRUITING

El Paso, Texas, 79932, United States
Climb Bio Investigative Site #104
RECRUITING

Sherman, Texas, 75092, United States
Climb Bio Investigative Site #105
RECRUITING

Orlando, Florida, 32086, United States
Climb Bio Investigative Site #106
RECRUITING

Indianapolis, Indiana, 46268, United States
Climb Bio Investigative Site #108
RECRUITING

Atlanta, Georgia, 30342, United States
Climb Bio Investigative Site #110
RECRUITING

Denver, Colorado, 80220, United States
Climb Bio Investigative Site #204
RECRUITING

Taichung, 404, Taiwan
Climb Bio Investigative Site #205
NOT_YET_RECRUITING

Taipei, 112, Taiwan
Climb Bio Investigative Site #501
RECRUITING

Porto Alegre, 90020-090, Brazil
Climb Bio Investigative Site #502
RECRUITING

Belo Horizonte, 30150-320, Brazil
Climb Bio Investigative Site #503
RECRUITING

São Paulo, 05403-000, Brazil
Climb Bio Investigative Site #504
RECRUITING

São Paulo, 05403-000, Brazil
Climb Bio Investigative Site #505
RECRUITING

Minas Gerais, 36010-570, Brazil
Climb Bio Investigative Site #506
NOT_YET_RECRUITING

Pernambuco, 50670-901, Brazil
Climb Bio Investigative Site #601
RECRUITING

CABA, C1111, Argentina
Climb Bio Investigative Site #604
NOT_YET_RECRUITING

CABA, C1425, Argentina
Climb Bio Investigative Site #605
NOT_YET_RECRUITING

Córdoba, C1425, Argentina
Climb Bio Investigative Site #606
NOT_YET_RECRUITING

Santa Fe, S3000, Argentina
Climb Bio Investigative Site #802
RECRUITING

Ternopil, 46002, Ukraine
Climb Bio Investigative Site #803
RECRUITING

Ivano-Frankivsk, 76008, Ukraine
Climb Bio Investigative Site #804
RECRUITING

Rivne, 33027, Ukraine
Climb Bio Investigative Site #805
RECRUITING

Kyiv, 03151, Ukraine
Climb Bio Investigative Site #901
RECRUITING

Tbilisi, 0144, Georgia
Climb Bio Investigative Site #902
RECRUITING

Tbilisi, 0114, Georgia
Climb Bio Investigative Site #903
RECRUITING

Tbilisi, 0112, Georgia
Climb Bio Investigative Site# 201
RECRUITING

Taipei, 110, Taiwan
Climb Bio Investigative Site# 202
NOT_YET_RECRUITING

Taipei, 100, Taiwan
Climb Bio Investigative Site# 203
NOT_YET_RECRUITING

Taipei, 235, Taiwan
Climb Bio Investigative Site# 602
RECRUITING

Buenos Aires, B1629, Argentina
Climb Bio Investigative Site# 603
NOT_YET_RECRUITING

Buenos Aires, B1888, Argentina
Climb Bio Investigative Site# 801
RECRUITING

Kyiv, 02125, Ukraine

Conditions

Explore the condition pages connected to this study.

PRIMARY MEMBRANOUS NEPHROPATHY